“The two treatments, designed to work by binding to the virus’ skeletal protein to neutralize its ability to infect cells, were among the first drugs developed early in the pandemic,” he said.
He added: “But the virus has since evolved and mounting evidence from laboratory tests indicates that the efficacy of ‘sutrovimab’ and ‘cacerifimab-imdivimab’ treatments is limited in the face of the latest mutations in the virus. ‘
Consequently, “even the US health authority has excluded them”.
And experts from the World Health Organization said yesterday, Thursday, that they strongly advised not to use them to treat people with “Covid 19”, in retreat from previous conditional recommendations, as part of a series of new recommendations published by the British. Medical Journal.
The U.S. Food and Drug Administration withdrew sutrovimab, manufactured by GlaxoSmithKline and its partner Fair Biotechnology, from the local market in April.
The drug reached billions in sales and became one of the best-selling drugs produced by British companies last year.
The antibody combination cacerifimab-imdivimab, manufactured by Regeneron and its partner Roche, also generated billions in sales and was one of the best-selling drugs by US companies last year.
The FDA revised its stance on the treatment in January, limiting its use to a smaller group of patients, citing its diminishing potency against the “Omicron” mutant.
The European Medicines Regulatory Authority still recommends both treatments.
–
